Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows

Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows
A combination of MacroGenics' HER2 antibody margetuximab and standard chemotherapy is superior to Herceptin (trastuzumab) plus chemotherapy at extending the time to disease progression among advanced and pre-treated breast cancer patients whose tumors are positive for HER2 (human epidermal growth factor receptor 2), a Phase 3 trial shows. Specifically, the SOPHIA trial (NCT02492711) included breast cancer patients who had received at least two prior HER2-targeted treatments for their metastatic disease —including Genentech's Herceptin, Perjeta (pertuzumab), and Kadcycla (ado-trastuzumab emtansine) — but no more than three prior treatments in total. “There are currently no approved agents for the treatment of patients with metastatic HER2+ breast cancer who have previously received trastuzumab, pertuzumab and ado-trastuzumab emtansine," Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, said in a press release. "If margetuximab is approved, based on SOPHIA data, I believe that this agent could become a valuable treatment option for these patients.” Treatment for HER2-positive breast cancer normally includes HER2-targeted therapies. Herceptin and Perjeta are two antibodies that directly target the HER2 protein, working to stop its pro-tumor activities and to induce strong immune responses against cancer cells. Kadcycla is made of Herceptin's antibody bound to a cytotoxic compound, and is designed to enter and kill cancer cells once the antibody binds to HER2. While these approaches have significantly improved the survival outcomes of HER2-positive breast cancer patients, some still see their disease return. In these cases, it is likely that the cancer will
Subscribe or to access all post and page content.